Unmet needs in autoimmune liver diseases

Area of Science:

• Hepatology and Immunology
• Autoimmune Liver Diseases Research

Background:

• Autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis are distinct autoimmune liver diseases with unclear pathophysiology.
• Therapeutic advances in autoimmune liver diseases lag behind other autoimmune conditions, with limited data on novel immunotherapies.

Purpose of the Study:

• To highlight critical gaps and discuss potential solutions for autoimmune liver diseases.
• To foster interdisciplinary discussion among experts and patients on unmet needs in liver autoimmunity.

Main Methods:

• The content is based on discussions from the fourth Swiss Autoimmune Liver Disease Meeting.
• This opinion paper synthesizes expert and patient perspectives on current challenges and future directions.

Main Results:

• Identified knowledge gaps in innovative therapies, including immune checkpoint inhibitors and mRNA vaccines.
• Highlighted the need for more research on infections, microbiome, and drug effects on liver autoimmunity.
• Emphasized the importance of advancing radiological techniques, artificial intelligence, and understanding pediatric-adult phenotype relationships.

Conclusions:

• Urgent advancement is needed in precision therapies, understanding disease mechanisms, and integrating new technologies like AI.
• Increased patient involvement and focus on individual symptom burden are crucial for improving long-term treatment quality.
• The meeting served as a platform to identify unmet needs and propose collaborative solutions for autoimmune liver diseases.